Evaluate Vantage Homepage
But how different is ACU193 really?
But subgroup analyses from Trailblazer-Alz 2 show that earlier is better for donanemab.
The latest deal focuses on in vivo Crispr editing for sickle cell disease, and follows last year’s cancer collaboration.
Nash data are due for Terns and Inventiva, as Marinus aims to expand its rare disease offering.
Leqembi seeks full approval, while Takeda hopes for a dengue green light and Verrica looks to break its streak of bad luck.
With a focus on France and Germany, the company builder is also closing in on its final two targets.
Astrazeneca’s $85m Quell collaboration comes after Regeneron’s tie-up with Sonoma and Lilly’s deal with Trex.
Lilly is the latest group, after Biogen and Sanofi, to collaborate on Scribe’s novel approach to Crispr editing.